Alfredo Andres Celedon
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$17.3MFederal grants as PI23 awards
5Patents grantedLatest May 6, 2025
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
23 awards · $17.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 30, 2026 | NIH | SBIR Phase II Bloodstream infection detection directly on whole blood | $1.0M | SCANOGEN INC. |
| Jul 31, 2025 | NIH | SBIR Phase II Highly Multiplexed Single Molecule Tethering | $1000K | SCANOGEN INC. |
| Jun 12, 2025 | NIH | SBIR Phase II Bloodstream infection detection directly on whole blood | $1.0M | SCANOGEN INC. |
| May 22, 2025 | NIH | SBIR Phase II Culture and amplification-free bacterial sepsis diagnosis | $1.0M | SCANOGEN INC. |
| Jul 17, 2024 | NIH | SBIR Phase II Bloodstream infection detection directly on whole blood | $1.0M | SCANOGEN INC. |
| Jul 15, 2024 | NIH | SBIR Phase II Highly Multiplexed Single Molecule Tethering | $1000K | SCANOGEN INC. |
| May 16, 2024 | NIH | SBIR Phase II Culture and amplification-free bacterial sepsis diagnosis | $1000K | SCANOGEN INC. |
| Aug 17, 2023 | NIH | SBIR Phase II Highly Multiplexed Single Molecule Tethering | $1000K | SCANOGEN INC. |
| Jun 9, 2023 | NIH | SBIR Phase II Culture and amplification-free bacterial sepsis diagnosis | $1000K | SCANOGEN INC. |
| Apr 19, 2022 | NIH | SBIR Phase II Culture and amplification-free bacterial sepsis diagnosis | $299K | SCANOGEN INC. |
| Jan 13, 2022 | NIH | SBIR Phase II Bloodstream infection detection directly on whole blood | $989K | SCANOGEN INC. |
| Jan 21, 2021 | NIH | SBIR Phase II Bloodstream infection detection directly on whole blood | $994K | SCANOGEN INC. |
| Feb 7, 2020 | NIH | SBIR Phase II Bloodstream infection detection directly on whole blood | $1.0M | SCANOGEN INC. |
| Jan 29, 2019 | NIH | SBIR Phase II Rapid Molecular Detection of Tuberculosis without PCR amplification | $1000K | SCANOGEN INC. |
| Apr 27, 2018 | NIH | SBIR Phase I Research and screening platform for Alzheimer’s and other chronic diseases | $300K | SCANOGEN INC. |
| Jan 12, 2018 | NIH | SBIR Phase II Rapid Molecular Detection of Tuberculosis without PCR amplification | $998K | SCANOGEN INC. |
| May 12, 2017 | NIH | SBIR Phase I Research and screening platform for Alzheimer’s and other chronic diseases | $300K | SCANOGEN INC. |
| Feb 10, 2017 | NIH | SBIR Phase II Rapid Molecular Detection of Tuberculosis without PCR amplification | $998K | SCANOGEN INC. |
| May 10, 2016 | NIH | SBIR Phase I Bloodstream infection detection directly on whole blood | $225K | SCANOGEN INC. |
| Dec 15, 2015 | NIH | SBIR Phase I Rapid Molecular Detection of Tuberculosis without PCR amplification | $225K | SCANOGEN INC. |
| Jun 25, 2015 | NIH | SBIR Phase I Novel Circular Supercoiling Biosensors for MicroRNA Detection | $289K | SCANOGEN INC. |
| Jun 6, 2015 | NIH | SBIR Phase I Novel microarrays for DNA genotyping in the presence of excess background DNA | $350K | SCANOGEN INC. |
| May 2, 2015 | NIH | SBIR Phase I Twist-Sensor: Novel microarrays for multiplex detection of drug resistance | $300K | SCANOGEN INC. |
6 patents as inventor
- US 10179930SCANOGEN INC.Jan 15, 2019
- US 11505818SCANOGEN INC.Nov 22, 2022
- US 12291741SCANOGEN INC.May 6, 2025
- US 9382578SCANOGEN INC.Jul 5, 2016
- US 9382580SCANOGEN INC.Jul 5, 2016
- US SCANOGEN INC.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#15
Awards as PI#13
Patents#60
Companies
- SCANOGEN INC.Linked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.